Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
MMP16	P51512	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MMP14	P50281	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MINPP1	Q9UNW1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MILR1	Q7Z6M3	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MILR1	Q7Z6M3	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
MIF	P14174	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MIF	P14174	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MIF	P14174	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
MICU3	Q86XE3	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
MICAL3	Q7RTP6	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
MIA	O15394	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
MGST3	O14880	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MGP	P08493	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
MGLL	Q99685	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
MGAT5	Q09328	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MGAT3	Q09327	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MGAT1	P26572	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MFGE8	F5H7N9	Bereman et al. 2018	ALS – Control	CSF	Down	33 ALS, 30 control
METTL7A	H0YI09	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
METRNL	Q641Q3	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
METAP2	P50579	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
MET	P08581	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MERTK	Q12866	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MERTK	Q12866	Zhou et al. 2023	SO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
MEPE	Q9NQ76	Zhou et al. 2023	SO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
MEGF8	Q7Z7M0	Oh et al. 2023	ALS – Control	CSF	Down	20 ALS, 20 control		59
MEGF8	Q7Z7M0	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
MEGF10	Q96KG7	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
MECR	Q9BV79	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
ME2	P23368	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MDH2	P40926	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MDH2	P40926	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MDH1	P40925	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MCTS1	Q9ULC4	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
MCTS1	Q9ULC4	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
MCAM	P43121	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
MCA3	O43324	Andrés-Benito et al. 2020	ALS – Control	CSF	Down	15 ALS, 15 control		61 ± 10.8
MBP	P02686	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MBL2	P11226	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
MBL2	P11226	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MATN3	O15232	Zhou et al. 2023	SO-ALS – Control	CSF	Down	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
MAT2B	Q9NZL9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAT2B	Q9NZL9	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
MAT2A	P31153	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAST1	Q9Y2H9	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
MASP2	O00187	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MASP1	P48740	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
MASP1	P48740	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MASP1	P48740	Zubiri et al. 2018	Late ALS – Early ALS (ALS slow cohort)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
MARS1	P56192	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
MARCO	Q9UEW3	Hayashi et al. 2020	ALS – Control	CSF exosome-enriched fractions	Down	3 ALS, 3 control		74.3
MARCKS	P29966	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MAPRE3	Q9UPY8	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MAPRE3	Q9UPY8	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
MAPRE1	Q15691	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
MAPK3	P27361	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAPK2	P49137	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
MAPK1	P28482	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
MAPK1	P28482	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAP6D1	Q9H9H5	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MAP6	Q96JE9	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MAP6	Q96JE9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAP4	F8W9U4	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MAP4	P27816	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAP2K1	Q02750	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAP2	P11137	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
MAP2	P11137	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
MAP2	P11137	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
MAP2	P11137	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
MAP1LC3B	Q9GZQ8	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
MAP1B	P46821	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
MAP1B	P46821	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
MAP1A	P78559	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MAOB	P27338	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
MAN2C1	H3BRI3	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
MAN1C1	Q9NR34	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
MAL2	Q969L2	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
MADD	Q8WXG6	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
MACF1	H0Y390	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
M6PR	P20645	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
LYZ	P61626	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LYVE1	Q9Y5Y7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LYSC	P61626	Oh et al. 2023	ALS – Control	CSF	Up	20 ALS, 20 control		59
LXN	Q9BS40	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
LUM	P51884	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
LTF	P02788	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTBP4	Q8N2S1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTBP3	Q9NS15	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTBP2	Q14767	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTBP1	Q14766	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTA4H	P09960	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
LTA4H	P09960	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
LTA4H	P09960	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
LSM8	F2Z2Y6	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
LSM7	Q9UK45	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
LSM3	P62310	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
LRRC47	Q8N1G4	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
LRRC47	Q8N1G4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
LRPPRC	P42704	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
LRPAP1	P30533	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)